Engflag

V.F.

Quick links to important sections

V.F.

V.F._EN

Method of action: Antibiotics And Chemotherapeutics For Dermatological Use, Antiherpetic, Antivirals For Systemic Use

Treatment option: Varicella-Zoster, Chickenpox, Genital Herpes, Cold Sore, Skin Conditions, Infection, Empeines, Shingles, Smallpox

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of V.F.

Property Description
Active Ingredient Aciclovir (Acyclovir)
Form Tablets, Creams, Solutions for Infusion
Pharmacological Class Antiviral, Synthetic Nucleoside Analogue
General Purpose To inhibit the multiplication of herpesviruses
Origin Synthetic (Chemically manufactured)

V.F. is a medicinal product defined by its active component, Aciclovir (INN), a core compound that is officially classified as a synthetic nucleoside analogue. It functions as an antiviral agent, meaning its purpose is to specifically impede the reproductive cycle of certain viral pathogens. Aciclovir is used exclusively as a single-ingredient product to address infections caused by the herpesvirus family and is globally recognized as a first-line therapy for managing these conditions.

What Type of Medicine is V.F. and What is its Composition?

V.F. belongs to the pharmacological class of antivirals because its composition, built around Aciclovir, is engineered to directly interfere with viral processes.

Aciclovir is specifically a purine nucleoside analogue, structurally mimicking the natural building blocks of viral DNA. This design is crucial for its function, as it allows the compound to be selectively activated by the enzyme viral thymidine kinase, which is predominantly found in herpesvirus-infected cells. This mechanism allows the drug to target infected cells due to its high specificity against the target viruses. The substance is entirely chemically manufactured, confirming its synthetic origin.

What Physical Forms Does Aciclovir Come In?

Aciclovir is available in various dosage forms to accommodate different therapeutic needs, including oral solids (tablets or capsules), topical semi-solids (creams or ointments), and a sterile solution for infusion (for intravenous administration).

The availability of these different forms is a distinguishing feature of Aciclovir, enabling both systemic use (oral and intravenous) to treat widespread infections and localized topical treatment for external skin lesions. Forms designed for systemic use deliver the active ingredient throughout the body, while topical forms offer a local, targeted approach.

What is the General Therapeutic Purpose of this Antiviral?

The general purpose of V.F. is to provide a foundational antiviral defense by stopping specific viruses from multiplying and spreading within the body.

The fundamental mechanism is selective inhibition: the drug is engineered to halt the reproduction process of the target virus. By incorporating itself into and terminating the viral DNA chain, the medicine effectively reduces the viral load. This action assists the body's immune system in managing the infection, which is the underlying benefit derived from its classification as a highly targeted, mechanism-based antiviral therapy.

Regulatory References

  1. Acyclovir - DailyMed

What side effects are possible with V.F.?

Possible Side Effects and Safety Information for V.F.

Serious and Clinically Significant Adverse Reactions

The use of V.F. is associated with a risk of serious and clinically significant adverse reactions, requiring careful safety monitoring. Officially documented risks include myelosuppression, encompassing conditions such as leukopenia, thrombocytopenia, and pancytopenia. V.F. has also been linked to severe events affecting organ systems, notably acute hepatic failure and the potential for severe hypersensitivity reactions, including anaphylaxis.

Cardiovascular Safety Profile

A critical safety consideration for V.F. is its effect on cardiac rhythm. Regulatory agencies mandate specific monitoring for potential QTc interval prolongation and pro-arrhythmic risk. Defined thresholds exist in official guidelines for the degree of QTc prolongation that necessitates drug discontinuation to manage this risk.

Adverse Reaction Occurrence

Adverse reactions are classified by frequency, typically using established regulatory frameworks (e.g., Very Common, Common, Uncommon) based on incidence rates from clinical trials. Furthermore, some toxicities, such as myelosuppression, exhibit dose- and time-dependent patterns, meaning the frequency or severity may increase with higher doses or prolonged exposure.

Safety Precautions and Monitoring

Safety-related restrictions and precautions include the need for specific, prolonged patient observation following administration to detect delayed toxicity. The official use context requires continuous monitoring schemes to assess for signs of adverse events, particularly in high-risk patients or those with pre-existing conditions that may predispose them to specific toxicities.

Overdose and Emergency Response

Overdose Manifestations and Risk Factors

Officially documented overdose presentations involve two primary physiological systems: the Central Nervous System (CNS) and the Renal System. Symptoms include neurological manifestations such as confusion, agitation, hallucinations, seizures, and progression to somnolence and coma. Renal impairment can occur, particularly following rapid intravenous infusion, which is associated with the precipitation of Aciclovir crystals in the renal tubules, leading to elevated serum creatinine and blood urea nitrogen. While high single oral doses are generally stated to be without toxic effects, repeated accidental overdosage has been associated with gastrointestinal effects. Elderly patients and individuals with pre-existing renal impairment are noted to be at increased risk of developing neurological side effects.

Regulatory Overview and Management

The regulatory materials classify overdose outcomes as potentially ranging from minimal to severe and life-threatening. No specific antidote is known. Management is defined as symptomatic and supportive treatment. Haemodialysis is documented as a procedure that significantly enhances the removal of the substance from the blood, and maintaining adequate hydration is advised to mitigate renal toxicity.

Official Emergency Action Statements

Immediate medical attention is required for life-threatening events. Regulatory guidance explicitly states that emergency services must be contacted if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Patients should be closely observed for signs of toxicity.

Therapeutic Uses of V.F.

V.F., which contains Aciclovir, is commonly used to address the symptomatic burden of infections caused by the Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV). Its therapeutic purpose is to provide supportive symptom management during acute and recurrent viral episodes.

Aciclovir is relevant in conditions involving episodic or fluctuating manifestations. It helps to relieve pain and discomfort and supports symptomatic relief in conditions such as Genital Herpes, Herpes Simplex Labialis (cold sores), Herpes Zoster (Shingles), and Varicella (Chickenpox).

“V.F. is commonly used when short-term symptomatic assistance is needed to help patients cope more steadily with difficult manifestations.”

A therapeutic benefit is that it contributes to the easing of discomfort and may assist with functional stability during an acute episode. It is considered relevant in clinical settings involving acute or unstable symptom patterns, such as severe manifestations in immunocompromised patients, and is applied in addressing conditions marked by increased physiological stress.

Quick Fact: Relief for Painful Skin Manifestations

V.F. is relevant for managing symptom clusters that may become intense or disruptive, helping to ease the physical discomfort of blisters, sores, and associated burning or itching.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using V.F. (Aciclovir) is strictly governed by regulatory documentation based on a patient's medical history and physiological state.

Absolute Contraindication

The medicine is contraindicated and must not be used by individuals with a known, documented history of hypersensitivity (a severe allergic reaction) to Aciclovir, its related prodrug valaciclovir, or any components of the specific formulation.

Conditional Use and Restrictions

Use is highly conditional for certain populations. Because V.F. is primarily cleared by the kidneys, patients with pre-existing renal impairment require an explicit dose adjustment mandated by regulatory guidelines. Similarly, older adults are eligible but require careful consideration for a dose reduction due to the likelihood of age-related decline in kidney function.

For pregnancy, use is permitted only if the potential benefits are determined to outweigh the potential risks to the fetus. During lactation (breastfeeding), use is generally allowed but should proceed with caution. Furthermore, caution is advised for patients with pre-existing neurological abnormalities due to an increased risk of central nervous system effects. The topical cream formulation is not recommended for use on mucous membranes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The interaction profile of V.F. (Aciclovir) is primarily determined by its dependence on active renal tubular secretion for elimination, a mechanism documented in regulatory prescribing information.

Property Description
Medicinal product categories with documented interactions Agents that share the same active renal tubular secretion elimination pathway; potentially nephrotoxic agents.
Specific interacting medicines (if explicitly listed) Probenecid, Cimetidine, Mycophenolate Mofetil (MMF), and Theophylline.
Mechanistic basis of interactions Pharmacokinetic interaction driven by competitive inhibition of active renal tubular secretion; also, pharmacodynamic interaction leading to additive organ toxicity risk.
Population-specific interaction notes Elderly patients and those with renal impairment are at heightened risk of toxicity due to reduced drug clearance.
Interaction-related restrictions Co-administration with Talimogene Laherparepvec is restricted due to pharmacodynamic antagonism.

Official Interaction Statements

Co-administration of Probenecid is officially documented to reduce V.F.'s renal clearance, resulting in an increase in its plasma AUC through transporter competition. Concurrently, V.F. is associated with an approximately 50% increase in the AUC of Theophylline, a clinically significant exposure modification that requires monitoring. Co-administration with potentially nephrotoxic agents carries an additive pharmacodynamic risk of kidney dysfunction and CNS symptoms.

Mechanism of Action

Modulating the Heart's Electrical Activity (Ion Channel Blockade)

V.F. functions as a multichannel blocker, exerting its primary effect by inhibiting voltage-gated potassium channels within cardiac cell membranes. This blockade prolongs the repolarization phase of the cardiac action potential, thereby lengthening the electrical recovery period (refractory period) of the heart tissue. This mechanism, combined with concurrent modulation of sodium and calcium channels, slows the speed and excitability of electrical signal propagation through the heart. This action contributes to the reduction of disorganized electrical firing and promotes the regulation of the heart's electrical cycle.

Regulating Conduction and Automaticity (Adrenergic System Influence)

The drug's effect extends to the autonomic nervous system through inhibition of adrenergic receptors (alpha and beta). By dampening the stimulating effects of the sympathetic nervous system, V.F. further contributes to reducing the heart's intrinsic spontaneous electrical firing (automaticity) and slowing its rate. This secondary regulatory action modulates the influence of sympathetic activity on the cardiac electrical cycle. The overall physiological consequence of these combined mechanisms is a regulated pattern of the heart's electrical impulses.

Dosage and Administration Information

How V.F. is Used (Aciclovir)

Aciclovir (V.F.) is administered using several officially approved methods, including oral forms (tablets, capsules, suspension), intravenous (IV) infusion, and topical preparations (creams, ointments). The choice of administration route depends on the infection's severity and location.

Official Dosing and Frequency

The required dosage and frequency are strictly dependent on the specific condition being addressed. For treating acute Herpes Simplex Virus (HSV) episodes, the standard oral regimen is 200 mg five times a day. In contrast, treatment for Herpes Zoster (Shingles) requires a higher oral dose of 800 mg five times a day. For long-term suppressive therapy against recurrent genital herpes, the regimen is typically 400 mg twice a day.

Administration Requirements

Condition Instruction Principle
Timing of Intake Oral forms may be administered with or without food.
IV Administration Must be given by slow intravenous infusion over a period of at least one hour; rapid injection is strictly prohibited.
Treatment Duration Acute treatment courses are time-bound, typically lasting 5 to 10 days. Suppressive therapy may continue for up to 12 months, requiring periodic re-evaluation.

Population and Renal Adjustments

Dosing is subject to mandatory modification based on a patient's kidney function, as the drug is primarily eliminated by the kidneys. For older adults and patients with renal impairment, a dose reduction or extension of the interval between doses is required based on their calculated creatinine clearance (CrCl). Adequate fluid intake is also a necessary procedural condition for all patients receiving high doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for V.F.

This overview describes the clinical research conducted for V.F. (Aciclovir), based only on official regulatory summaries and peer-reviewed scientific literature. The research helps to contextualize the patterns observed when V.F. was studied for infections caused by the herpesvirus family.

Evidence for Use in Genital Herpes and Cold Sores (Herpes Simplex Virus, HSV)

V.F. has been extensively studied for conditions characterized by fluctuating or episodic manifestations, specifically for research exploring initial and recurrent episodes of genital herpes and oral cold sores. Research in this area primarily involves Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews.

The research examined outcomes related to physical discomfort, monitoring factors such as the time needed for lesions to complete the healing process and the duration of pain and other acute symptoms. The existing evidence focuses on research exploring active disease and recurrence frequency, but data are still emerging concerning the medicine’s ability to affect the latent virus that causes the infection.

Evidence for Use in Shingles (Herpes Zoster Virus, VZV)

Research exploring V.F. was studied for shingles in RCTs and Systematic Reviews. The studies examined outcomes related to physical discomfort, monitoring factors such as the time to complete resolution of the rash and the incidence of prolonged nerve pain known as Post-Herpetic Neuralgia (PHN).

Research describes patterns related to measured outcomes focusing on episodic or acute changes when V.F. was administered early in the course of the infection. However, findings regarding the precise effect on the incidence of prolonged pain (PHN) were mixed across different studies, and certainty remains low in this specific outcome.

Evidence Gaps and Uncertainties

The current evidence landscape highlights several areas where research is limited. For example, comparative evidence is lacking in direct, head-to-head trials against all newer antiviral medicines across all indications. The efficacy of topical formulations is generally noted as minimal compared to systemic treatment. Furthermore, research provides insight into short-term changes, but there is limited information for long-term outcomes related to the durability of the effect after treatment is completed.

Key Studies & References

  1. Acyclovir: NIH MedlinePlus Drug Information Overview

How should V.F. be stored and disposed of?

How to Store and Dispose of V.F.

The storage and disposal of V.F. (Aciclovir) must adhere strictly to regulatory requirements to maintain product stability and ensure safety.

Storage Conditions

  • Temperature: V.F. tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must not be frozen.
  • Protection: The medicine must be kept protected from moisture and stored in its original container with the lid tightly closed.
  • Child Safety: To prevent accidental exposure, V.F. must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused V.F. should not be disposed of in household waste or wastewater.

Disposal must follow local regulatory requirements, which often involve using a pharmacy or community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of V.F. found in:

A-Z Index: